Gilder Gagnon Howe Co Lowers stake in DexCom (DXCM)

DexCom (DXCM) : Gilder Gagnon Howe Co reduced its stake in DexCom by 2.61% during the most recent quarter end. The investment management company now holds a total of 786,047 shares of DexCom which is valued at $71,428,091 after selling 21,073 shares in DexCom , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.DexCom makes up approximately 1.32% of Gilder Gagnon Howe Co’s portfolio.

Other Hedge Funds, Including , Pillar Pacific Capital Management boosted its stake in DXCM in the latest quarter, The investment management firm added 7 additional shares and now holds a total of 5,507 shares of DexCom which is valued at $500,421. DexCom makes up approx 0.08% of Pillar Pacific Capital Management’s portfolio. Parametrica Management Ltd added DXCM to its portfolio by purchasing 3,198 company shares during the most recent quarter which is valued at $281,072. DexCom makes up approx 0.40% of Parametrica Management Ltd’s portfolio. Cibc World Markets added DXCM to its portfolio by purchasing 22,651 company shares during the most recent quarter which is valued at $1,990,796. DexCom makes up approx 0.01% of Cibc World Markets’s portfolio.Eqis Capital Management boosted its stake in DXCM in the latest quarter, The investment management firm added 119 additional shares and now holds a total of 7,246 shares of DexCom which is valued at $566,565. DexCom makes up approx 0.04% of Eqis Capital Management’s portfolio. Washington Trust Bank added DXCM to its portfolio by purchasing 26 company shares during the most recent quarter which is valued at $2,051.

DexCom opened for trading at $91.5 and hit $91.77 on the upside on Thursday, eventually ending the session at $91.5, with a gain of 0.69% or 0.63 points. The heightened volatility saw the trading volume jump to 9,86,516 shares. Company has a market cap of $7,634 M.

On the company’s financial health, DexCom reported $-0.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.12. The company had revenue of $137.30 million for the quarter, compared to analysts expectations of $132.54 million. The company’s revenue was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.

Many Wall Street Analysts have commented on DexCom. Company shares were Reiterated by The Benchmark Company on Aug 3, 2016 to “Buy”, Firm has raised the Price Target to $ 106 from a previous price target of $86 .

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Leave a Reply

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.